русский 
Kreyòl Ayisyen
Gaeilgenah Éireann
Norsk
Srbija jezik (latinica)
bosanski
Português
Français
magyar
বাংলা
Polski
The quality of a pharmaceutical excipient is not determined by its specification sheet alone, but by its consistency, traceability, and suitability for the intended formulation.Selecting pharmaceutical-grade Copovidone VA64 requires more than comparing prices and checking a supplier's product catalogue. For pharmaceutical manufacturers, excipient quality can influence tablet hardness, granulation performance, film formation, drug dissolution, and batch-to-batch consistency. An unsuitable material may lead to formulation adjustments, production delays, or additional quality investigations. Copovidone VA64, also known as copolyvidone or PVP/VA copolymer, is a vinylpyrrolidone-vinyl acetate copolymer widely used in pharmaceutical formulations. Its binding and film-forming properties make it relevant to tablet manufacturing, wet granulation, dry binding, and selected solid dispersion applications.Before purchasing pharmaceutical-grade Copovidone VA64, buyers should evaluate the material's compendial compliance, critical quality attributes, analytical documentation, manufacturing controls, and long-term supply reliability.
Copovidone VA64 Purchasing Evaluation Checklist
The following table provides a practical framework for comparing pharmaceutical-grade Copovidone VA64 suppliers before requesting quotations or approving a new raw material source.
| Evaluation Factor | What Buyers Should Check | Why It Matters |
|---|---|---|
| Product identity | Copovidone, VP/VA copolymer, CAS No. 25086-89-9 | Confirms the intended polymer |
| Pharmacopeial compliance | Applicable USP/NF, Ph. Eur., and JP requirements | Supports pharmaceutical quality assessment |
| Critical specifications | K value, residual monomers, moisture, impurities, and solution appearance | Helps assess material consistency |
| Batch documentation | Certificate of Analysis (COA) and approved specifications | Enables batch-level verification |
| Quality system | Manufacturing controls, change control, deviation handling, and traceability | Supports supplier qualification |
| Application suitability | Binding, granulation, coating, or solid dispersion performance | Connects material properties with formulation needs |
| Packaging and storage | Container integrity, moisture protection, and storage conditions | Helps preserve material quality |
| Supply capability | Production capacity, lead time, and continuity planning | Reduces procurement and production risks |
A reliable purchasing decision should combine documentary review, laboratory evaluation, supplier qualification, and application testing rather than depend on a single specification or commercial quotation.
Verify the Identity and Pharmaceutical Grade of Copovidone VA64
The first step is to confirm that the material offered is the correct polymer and grade.
Copovidone VA64 is a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate. Its commonly referenced CAS number is 25086-89-9, and its chemical identity is associated with VP/VA copolymer terminology.
Although suppliers may use different commercial names, buyers should verify that the offered product corresponds to the intended pharmaceutical excipient rather than a cosmetic-grade or industrial-grade material.
Request the product specification and confirm the following:
Chemical identity and CAS number
Intended pharmaceutical application and grade designation
Applicable pharmacopoeial requirements
Manufacturer's product code and batch identification
Current technical documentation
Pharmaceutical-grade Copovidone VA64 should be evaluated against the standards applicable to the target product and destination market. A supplier's general statement that its material meets international standards is not a substitute for reviewing the relevant specification and supporting documentation.
Evaluate Critical Quality Attributes Before Purchasing
The next step is to examine the parameters that influence material quality and manufacturing performance.
Different Copovidone VA64 products may share the same chemical identity while differing in specification limits, manufacturing controls, and demonstrated application performance.
Key specifications to review
| Quality Attribute | What to Evaluate |
|---|---|
| K value | Confirm the specified range and its relationship to the intended polymer grade |
| Residual monomers | Review the applicable limits and validated analytical methods |
| Aldehydes | Verify compliance with the approved product specification |
| Peroxides | Assess the specified limit and analytical results |
| Hydrazine | Confirm the applicable limit and test result |
| Loss on drying | Evaluate moisture-related requirements and storage implications |
| Sulfated ash | Review the limit for inorganic residue |
| Solution appearance | Check the defined acceptance criteria |
| Vinyl acetate content | Verify the applicable assay or compositional requirements |
These parameters should be assessed against the supplier's current approved specification and the applicable pharmacopoeial monograph. Limits and test methods should not be assumed to be identical across every specification or market.
K value is particularly useful when assessing polymer characteristics, but it should not be treated as a complete predictor of binding efficiency or dissolution performance. Formulation composition, processing conditions, and other material properties also affect the final result.
For example, buyers comparing two Copovidone VA64 suppliers should examine actual batch data and the consistency of results rather than choosing the material with the lowest price or the narrowest advertised K-value range alone.
Review the COA and Supporting Quality Documents
A Certificate of Analysis is one of the most important documents in pharmaceutical excipient procurement. It records analytical results for a particular batch and allows the buyer to compare those results with the approved acceptance criteria.
When sourcing pharmaceutical-grade Copovidone VA64, request the following documents as applicable:
Certificate of Analysis (COA): Batch-specific test results and acceptance criteria.
Technical Data Sheet (TDS): Product characteristics, specifications, and recommended handling information.
Safety Data Sheet (SDS): Relevant hazard, handling, storage, and transport information.
Pharmacopeial compliance statement: Identification of the applicable compendial requirements.
Quality-system documentation: Relevant information about the manufacturer's quality management practices.
Regulatory support documents: Available documentation required for the intended registration, customer qualification, or target market.
Additional records may be necessary depending on the pharmaceutical company's internal procedures and regulatory obligations.
Buyers should also check whether the COA identifies the correct manufacturer, product grade, batch number, testing date, and specification revision. Any discrepancies should be clarified before material approval.
Where required, confirm whether the supplier can support audits, technical questionnaires, change notifications, and investigations into out-of-specification results.
Assess Copovidone VA64 Performance in the Intended Formulation
Pharmaceutical-grade Copovidone VA64 is valued for its versatility, but its suitability must be demonstrated in the intended manufacturing process.
Copovidone VA64 can function as a binder in wet granulation and dry-binding processes. It helps particles adhere to one another and can contribute to tablet mechanical strength.
During formulation trials, evaluate granule formation, flow characteristics, compression behavior, tablet hardness, friability, and disintegration. The appropriate binder concentration depends on the formulation and manufacturing process.
Copovidone VA64 can also serve as a film-forming polymer in suitable pharmaceutical coating systems. Buyers should examine film uniformity, adhesion, flexibility, and compatibility with other formulation ingredients.
Solvent selection and processing conditions should be established through formulation development rather than assumed from the polymer's general solubility profile.
Copovidone VA64 is used in selected formulations involving poorly water-soluble active pharmaceutical ingredients. It may help maintain an amorphous drug state and improve dissolution performance when the polymer, drug, and process are appropriately matched.
However, the effect is formulation-dependent. Buyers should evaluate physical stability, drug-polymer compatibility, dissolution behavior, and the risk of recrystallization before selecting a grade for commercial production.
The practical objective is to determine whether the material performs consistently under the buyer's actual processing conditions, not simply whether it passes incoming raw-material tests.
Qualify the Copovidone VA64 Manufacturer
A supplier's manufacturing experience and quality controls are important indicators of long-term procurement reliability.
Huzhou Sunflower Pharmaceutical Co., Ltd.
Huzhou Sunflower Pharmaceutical Co., Ltd. is a pharmaceutical excipient manufacturer specializing in PVP-related polymers and derivatives, including povidone, crospovidone, and copovidone VA64. The company's SUNVIDONE® VA product information identifies Copovidone VA64 as a vinylpyrrolidone-vinyl acetate copolymer used in pharmaceutical applications.
Its product portfolio and technical information are relevant to buyers evaluating pharmaceutical-grade PVP and copovidone materials.
Key points for prospective buyers include:
Product specialization: A portfolio covering PVP series products, crosslinked PVP, and copovidone supports sourcing discussions across related polymer excipients.
Pharmaceutical specifications: The published SUNVIDONE® VA information references USP/NF, European Pharmacopoeia, and Japanese Pharmacopoeia requirements. Buyers should confirm the current specification and applicable compliance documentation for the exact grade offered.
Application versatility: Copovidone VA64 is used as a binder for tablets and granules and can support suitable film-forming and other formulation applications.
Technical evaluation: Buyers can discuss product specifications, application requirements, and documentation needs before proceeding with sample testing and supplier qualification.
For procurement teams, the next step is to request the current product specification, a representative COA, applicable quality documentation, and a sample for evaluation.
Product information is available at SUNVIDONE® VA64 pharmaceutical-grade Copovidone.
Compare Supply Reliability, Packaging, and Total Purchasing Cost
A competitive quotation is useful only when the quoted material meets the required quality and supply conditions.
When comparing Copovidone VA64 manufacturers, evaluate the total purchasing cost rather than the price per kilogram alone.
Important commercial considerations include:
Minimum order quantity and available order sizes
Standard packaging options and container integrity
Production and shipment lead times
Export documentation and delivery terms
Sample availability and technical communication
Batch traceability and procedures for handling quality complaints
Supply continuity for repeat and commercial-scale orders
Copovidone VA64 is commonly supplied in fiber drums or suitable polymer drums, with packaging configurations depending on the supplier. The packaging specification should define the net weight, protective measures, and storage requirements.
Before placing a bulk order, buyers should confirm that the proposed packaging and transportation arrangements are compatible with their receiving, storage, and material-handling procedures.
A supplier capable of providing consistent batches, clear documentation, and dependable communication may offer better long-term value than a supplier selected solely on the lowest initial price.
Conduct Sample Testing and Final Supplier Approval
Sample evaluation is an important step before commercial procurement, particularly when introducing a new Copovidone VA64 source or changing an established excipient supplier.
A structured qualification process should include:
Document review: Compare the specification, COA, and other required records against internal acceptance criteria.
Laboratory testing: Verify relevant identity and quality attributes using approved methods.
Formulation trials: Evaluate the material in the intended process, including granulation, compression, coating, or solid dispersion development where applicable.
Risk assessment: Consider the effects of material variability on product quality, process robustness, and stability.
Supplier approval: Complete the required quality review, audit, and procurement approval procedures.
Ongoing monitoring: Review incoming batch results and investigate significant changes or recurring deviations.
A sample that performs well in a laboratory trial is not, by itself, proof of long-term commercial consistency. Buyers should establish clear acceptance criteria and ensure that the approved material remains aligned with the qualified specification.
Frequently Asked Questions About Pharmaceutical-Grade Copovidone VA64
Copovidone VA64 is primarily used as a binder in tablet and granule manufacturing. Depending on the formulation, it can also serve as a film-forming polymer and a component of solid dispersion systems intended to improve the dissolution performance of selected poorly soluble drugs.
Copovidone VA64 is a copolymer of vinylpyrrolidone and vinyl acetate, whereas Povidone K30 is a homopolymer of vinylpyrrolidone. Their composition and material characteristics differ, so they should not be considered interchangeable without formulation-specific evaluation.
At minimum, request the current product specification, batch-specific COA, TDS, and SDS. Depending on the intended application and regulatory requirements, additional pharmacopeial compliance statements, quality-system records, and regulatory support documents may be needed.
Compare COAs across multiple batches, review critical quality attributes, and verify that the supplier follows documented manufacturing and change-control procedures. Incoming testing and periodic performance checks can help identify meaningful variation before it affects production.
It can support dissolution enhancement in suitable formulations, particularly when used in appropriately designed solid dispersion systems. Results depend on the active ingredient, polymer ratio, manufacturing process, and physical stability of the resulting formulation. Experimental validation is essential.
Prioritize pharmaceutical-grade suitability, documented quality controls, reliable batch traceability, technical support, production capacity, and consistent delivery. Price, packaging, lead time, and regulatory documentation should also be evaluated as part of the overall supplier qualification process.
Conclusion
Evaluating pharmaceutical-grade Copovidone VA64 before purchasing requires a systematic review of product identity, critical quality attributes, documentation, formulation performance, and supplier reliability. Buyers should verify applicable USP/NF, Ph. Eur., or JP requirements, review batch-specific analytical results, and test the material in its intended pharmaceutical application before approving commercial supply.
Huzhou Sunflower Pharmaceutical Co., Ltd. is a relevant manufacturer for procurement teams sourcing Copovidone VA64 and related PVP excipients. By combining a clear technical specification, appropriate quality documentation, formulation testing, and a structured supplier qualification process, pharmaceutical manufacturers can make more informed purchasing decisions and reduce the risks associated with raw-material variability.
The most effective purchasing strategy is to select a Copovidone VA64 supplier that can demonstrate product suitability, support quality requirements, and maintain consistent supply throughout the product lifecycle.